Law360, New York (April 29, 2016, 9:46 PM EDT) -- Hospira has urged the U.S. Supreme Court not to review the invalidation of the asserted claims of four patents for Cubist Pharmaceutical's blockbuster antibiotic Cubicin, arguing that the Federal Circuit followed legal precedent in affirming that they were obvious.
Because the court's decision was based on a fact-intensive ruling that applied settled precedent as to obviousness, broke no ground and did not raise any important legal issue beyond the invalidity of the asserted claims, the high court does not need to engage in the "empty drama" raised by Cubist Pharmaceuticals Inc., according to the Wednesday opposition brief by Hospira Inc., which...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!